Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
The causative agent of the COVID-19 pandemic is undergoing several changes, and the evolutionary cascade of SARS-CoV-2 has led to the emergence of a range of variants of SARS-CoV-2. Additionally, the emergence of recombinant variants or super variants such as XBB.1.5, XBB.1.16, XBB.1.9.1, and XBB.1....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Health Sciences Review |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772632023000533 |
| _version_ | 1797394775366696960 |
|---|---|
| author | Manish Dhawan AbdulRahman A. Saied Manish Sharma |
| author_facet | Manish Dhawan AbdulRahman A. Saied Manish Sharma |
| author_sort | Manish Dhawan |
| collection | DOAJ |
| description | The causative agent of the COVID-19 pandemic is undergoing several changes, and the evolutionary cascade of SARS-CoV-2 has led to the emergence of a range of variants of SARS-CoV-2. Additionally, the emergence of recombinant variants or super variants such as XBB.1.5, XBB.1.16, XBB.1.9.1, and XBB.1.9.2 has raised several concerns among the scientific community regarding the efficacy of various vaccines. The scientists are still figuring out the consequences of the variants and recombinant variants, such as their implications for the emergence of reinfection. In this context, a range of vaccines have been developed to overcome the consequences of COVID-19, but they all come with their disadvantages. While considering the disadvantages and advantages of various vaccine platforms, scientists are exploring virus-like particles (VLPs) to develop vaccines against COVID-19. Therefore, an updated review of literature has been conducted to elucidate their usage of VLPs-based vaccines to manage COVID-19. Considering the consequences of the ongoing evolution of SARS-CoV-2, the article discusses the potential role of VLPs in the development of efficient and reliable vaccines against COVID-19. Further, we have explained how VLPs generate a potent and long-lasting immune response, along with the recent VLPs in clinical trials. Additionally, we have highlighted the limitations of VLPs along with possible solutions and future directions that will overcome such limitations. |
| first_indexed | 2024-03-09T00:24:34Z |
| format | Article |
| id | doaj.art-b6da28be73bb44dd854813ad1cbb126f |
| institution | Directory Open Access Journal |
| issn | 2772-6320 |
| language | English |
| last_indexed | 2024-03-09T00:24:34Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Health Sciences Review |
| spelling | doaj.art-b6da28be73bb44dd854813ad1cbb126f2023-12-12T04:37:16ZengElsevierHealth Sciences Review2772-63202023-12-019100127Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?Manish Dhawan0AbdulRahman A. Saied1Manish Sharma2Department of Microbiology, Punjab Agricultural University, Ludhiana 141004, Punjab, India; Trafford College, Altrincham, Manchester WA14 5PQ, UK; Corresponding author at: Department of Microbiology, Punjab Agricultural University, Ludhiana 141004, India, Trafford College, Altrincham, Manchester WA14 5PQ, UK.Ministry of Tourism and Antiquities, Aswan Office, Aswan 81511, EgyptUniversity Institute of Biotechnology, Department of Biotechnology, Chandigarh University, Mohali 140413, Punjab, IndiaThe causative agent of the COVID-19 pandemic is undergoing several changes, and the evolutionary cascade of SARS-CoV-2 has led to the emergence of a range of variants of SARS-CoV-2. Additionally, the emergence of recombinant variants or super variants such as XBB.1.5, XBB.1.16, XBB.1.9.1, and XBB.1.9.2 has raised several concerns among the scientific community regarding the efficacy of various vaccines. The scientists are still figuring out the consequences of the variants and recombinant variants, such as their implications for the emergence of reinfection. In this context, a range of vaccines have been developed to overcome the consequences of COVID-19, but they all come with their disadvantages. While considering the disadvantages and advantages of various vaccine platforms, scientists are exploring virus-like particles (VLPs) to develop vaccines against COVID-19. Therefore, an updated review of literature has been conducted to elucidate their usage of VLPs-based vaccines to manage COVID-19. Considering the consequences of the ongoing evolution of SARS-CoV-2, the article discusses the potential role of VLPs in the development of efficient and reliable vaccines against COVID-19. Further, we have explained how VLPs generate a potent and long-lasting immune response, along with the recent VLPs in clinical trials. Additionally, we have highlighted the limitations of VLPs along with possible solutions and future directions that will overcome such limitations.http://www.sciencedirect.com/science/article/pii/S2772632023000533COVID-19Immune responseSARS-CoV-2VaccinesVirus like particles (VLPs) |
| spellingShingle | Manish Dhawan AbdulRahman A. Saied Manish Sharma Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? Health Sciences Review COVID-19 Immune response SARS-CoV-2 Vaccines Virus like particles (VLPs) |
| title | Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? |
| title_full | Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? |
| title_fullStr | Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? |
| title_full_unstemmed | Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? |
| title_short | Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2? |
| title_sort | virus like particles vlps based vaccines against covid 19 where do we stand amid the ongoing evolution of sars cov 2 |
| topic | COVID-19 Immune response SARS-CoV-2 Vaccines Virus like particles (VLPs) |
| url | http://www.sciencedirect.com/science/article/pii/S2772632023000533 |
| work_keys_str_mv | AT manishdhawan viruslikeparticlesvlpsbasedvaccinesagainstcovid19wheredowestandamidtheongoingevolutionofsarscov2 AT abdulrahmanasaied viruslikeparticlesvlpsbasedvaccinesagainstcovid19wheredowestandamidtheongoingevolutionofsarscov2 AT manishsharma viruslikeparticlesvlpsbasedvaccinesagainstcovid19wheredowestandamidtheongoingevolutionofsarscov2 |